Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS

The Centers for Medicare and Medicaid Services will only pay for Kymriah if patients respond after one month. Novartis also pursuing similar contracts with private payers.

3d illustration of T cells or cancer cells
Novartis's Kymriah will be reimbursed under a groundbreaking arrangement

Novartis AG's newly-approved CAR-T treatment for childhood leukemia, Kymriah (tisagenlecleucel), will be reimbursed based on outcomes under a groundbreaking arrangement between the manufacturer and the Centers for Medicare and Medicaid Services.

Kymriah was cleared by FDA Aug. 30 for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access